ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Carcinoma, Hepatocellular
DRUG: ABX196
Incidence of adverse events (AEs), Adverse Events evaluated according to CTC-AE, Through study completion, an average of 1 year
Objective Response Rate (ORR), Partial and Complete response according to RECIST V1.1, From date of randomization until the date of first documented progression, assessed up to 12 months|Duration of Response (DOR), From date of randomization until the date of first documented progression, assessed up to 12 months|Progression-Free Survival, From date of randomization until the date of first documented progression, assessed up to 24 months|Alpha Fetoprotein Serum concentrations, Every 2 weeks, assessed up to 12 months
This is an open-label, uncontrolled phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma. The study consists of 2 phases, a Dose Escalation Phase and an Expansion Phase. Nivolumab will be administered, consistent with the US prescribing information, as a 30-minute IV infusion on Days 1 and 15 of each 28-Day cycle. ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day cycle (i.e., every 8 weeks).